{"entity_poly": {"nstd_linkage": "no", "nstd_monomer": "no", "pdbx_seq_one_letter_code": "QDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY", "pdbx_seq_one_letter_code_can": "QDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY", "pdbx_strand_id": "A", "rcsb_artifact_monomer_count": 1, "rcsb_conflict_count": 0, "rcsb_deletion_count": 0, "rcsb_entity_polymer_type": "Protein", "rcsb_insertion_count": 0, "rcsb_mutation_count": 0, "rcsb_non_std_monomer_count": 0, "rcsb_sample_sequence_length": 323, "type": "polypeptide(L)"}, "entity_src_gen": [{"gene_src_common_name": "human", "gene_src_genus": "Homo", "gene_src_tissue": "liver", "host_org_genus": "Escherichia", "host_org_species": "Escherichia coli", "pdbx_alt_source_flag": "sample", "pdbx_gene_src_ncbi_taxonomy_id": "9606", "pdbx_gene_src_scientific_name": "Homo sapiens", "pdbx_host_org_ncbi_taxonomy_id": "511693", "pdbx_host_org_scientific_name": "Escherichia coli BL21", "pdbx_host_org_strain": "BL21", "pdbx_host_org_vector_type": "PLASMID", "pdbx_src_id": 1, "plasmid_name": "pGEX"}], "rcsb_cluster_flexibility": {"avg_rmsd": 0.388, "label": "No", "link": "http://pdbflex.org/cluster.html#!/4l1xA/22532/1mrqA", "max_rmsd": 1.115, "provenance_code": "PDBFlex"}, "rcsb_cluster_membership": [{"cluster_id": 12237, "identity": 100}, {"cluster_id": 3157, "identity": 95}, {"cluster_id": 3533, "identity": 90}, {"cluster_id": 676, "identity": 70}, {"cluster_id": 239, "identity": 50}, {"cluster_id": 259, "identity": 30}], "rcsb_entity_host_organism": [{"ncbi_common_names": ["Escherichia coli str. BL21", "Escherichia coli strain BL21"], "ncbi_parent_scientific_name": "Bacteria", "ncbi_scientific_name": "Escherichia coli BL21", "ncbi_taxonomy_id": 511693, "pdbx_src_id": 1, "provenance_source": "Primary Data", "scientific_name": "Escherichia coli BL21", "taxonomy_lineage": [{"depth": 1, "id": "131567", "name": "cellular organisms"}, {"depth": 1, "id": "131567", "name": "biota"}, {"depth": 2, "id": "2", "name": "Bacteria"}, {"depth": 2, "id": "2", "name": "Bacteria (ex Cavalier-Smith 1987)"}, {"depth": 2, "id": "2", "name": "Bacteria Woese et al. 2024"}, {"depth": 2, "id": "2", "name": "Bacteriobiota"}, {"depth": 2, "id": "2", "name": "bacteria"}, {"depth": 2, "id": "2", "name": "eubacteria"}, {"depth": 3, "id": "3379134", "name": "Pseudomonadati"}, {"depth": 4, "id": "1224", "name": "Pseudomonadota"}, {"depth": 4, "id": "1224", "name": "\"Alphaproteobacteriota\" Whitman et al. 2018"}, {"depth": 4, "id": "1224", "name": "Alphaproteobacteriota"}, {"depth": 4, "id": "1224", "name": "Proteobacteria"}, {"depth": 4, "id": "1224", "name": "Proteobacteriota"}, {"depth": 4, "id": "1224", "name": "proteobacteria"}, {"depth": 4, "id": "1224", "name": "purple photosynthetic bacteria and relatives"}, {"depth": 5, "id": "1236", "name": "Gammaproteobacteria"}, {"depth": 5, "id": "1236", "name": "Proteobacteria gamma subdivision"}, {"depth": 5, "id": "1236", "name": "Pseudomonadia"}, {"depth": 5, "id": "1236", "name": "Purple bacteria, gamma subdivision"}, {"depth": 5, "id": "1236", "name": "g-proteobacteria"}, {"depth": 5, "id": "1236", "name": "gamma proteobacteria"}, {"depth": 5, "id": "1236", "name": "gamma subdivision"}, {"depth": 5, "id": "1236", "name": "gamma subgroup"}, {"depth": 6, "id": "91347", "name": "Enterobacterales"}, {"depth": 6, "id": "91347", "name": "Enterobacteriaceae and related endosymbionts"}, {"depth": 6, "id": "91347", "name": "Enterobacteriaceae group"}, {"depth": 6, "id": "91347", "name": "Enterobacteriales"}, {"depth": 7, "id": "543", "name": "Enterobacteriaceae"}, {"depth": 7, "id": "543", "name": "Enterobacteraceae"}, {"depth": 7, "id": "543", "name": "enterobacteria"}, {"depth": 8, "id": "561", "name": "Escherichia"}, {"depth": 9, "id": "562", "name": "Escherichia coli"}, {"depth": 9, "id": "562", "name": "Bacillus coli"}, {"depth": 9, "id": "562", "name": "Bacterium coli"}, {"depth": 9, "id": "562", "name": "Bacterium coli commune"}, {"depth": 9, "id": "562", "name": "E. coli"}, {"depth": 9, "id": "562", "name": "Enterococcus coli"}, {"depth": 9, "id": "562", "name": "Escherichia/Shigella coli"}, {"depth": 10, "id": "511693", "name": "Escherichia coli BL21"}, {"depth": 10, "id": "511693", "name": "Escherichia coli str. BL21"}, {"depth": 10, "id": "511693", "name": "Escherichia coli strain BL21"}]}], "rcsb_entity_source_organism": [{"common_name": "human", "ncbi_common_names": ["human"], "ncbi_parent_scientific_name": "Eukaryota", "ncbi_scientific_name": "Homo sapiens", "ncbi_taxonomy_id": 9606, "pdbx_src_id": 1, "provenance_source": "Primary Data", "scientific_name": "Homo sapiens", "source_type": "genetically engineered", "taxonomy_lineage": [{"depth": 1, "id": "131567", "name": "cellular organisms"}, {"depth": 1, "id": "131567", "name": "biota"}, {"depth": 2, "id": "2759", "name": "Eukaryota"}, {"depth": 2, "id": "2759", "name": "Eucarya"}, {"depth": 2, "id": "2759", "name": "Eucaryotae"}, {"depth": 2, "id": "2759", "name": "Eukarya"}, {"depth": 2, "id": "2759", "name": "Eukaryotae"}, {"depth": 2, "id": "2759", "name": "eukaryotes"}, {"depth": 3, "id": "33154", "name": "Opisthokonta"}, {"depth": 3, "id": "33154", "name": "Fungi/Metazoa group"}, {"depth": 3, "id": "33154", "name": "opisthokonts"}, {"depth": 4, "id": "33208", "name": "Metazoa"}, {"depth": 4, "id": "33208", "name": "Animalia"}, {"depth": 4, "id": "33208", "name": "animals"}, {"depth": 4, "id": "33208", "name": "metazoans"}, {"depth": 4, "id": "33208", "name": "multicellular animals"}, {"depth": 5, "id": "6072", "name": "Eumetazoa"}, {"depth": 6, "id": "33213", "name": "Bilateria"}, {"depth": 7, "id": "33511", "name": "Deuterostomia"}, {"depth": 7, "id": "33511", "name": "deuterostomes"}, {"depth": 8, "id": "7711", "name": "Chordata"}, {"depth": 8, "id": "7711", "name": "chordates"}, {"depth": 9, "id": "89593", "name": "Craniata"}, {"depth": 10, "id": "7742", "name": "Vertebrata"}, {"depth": 10, "id": "7742", "name": "vertebrates"}, {"depth": 11, "id": "7776", "name": "Gnathostomata"}, {"depth": 11, "id": "7776", "name": "jawed vertebrates"}, {"depth": 12, "id": "117570", "name": "Teleostomi"}, {"depth": 13, "id": "117571", "name": "Euteleostomi"}, {"depth": 13, "id": "117571", "name": "bony vertebrates"}, {"depth": 14, "id": "8287", "name": "Sarcopterygii"}, {"depth": 15, "id": "1338369", "name": "Dipnotetrapodomorpha"}, {"depth": 16, "id": "32523", "name": "Tetrapoda"}, {"depth": 16, "id": "32523", "name": "tetrapods"}, {"depth": 17, "id": "32524", "name": "Amniota"}, {"depth": 17, "id": "32524", "name": "amniotes"}, {"depth": 18, "id": "40674", "name": "Mammalia"}, {"depth": 18, "id": "40674", "name": "mammals"}, {"depth": 19, "id": "32525", "name": "Theria"}, {"depth": 20, "id": "9347", "name": "Eutheria"}, {"depth": 20, "id": "9347", "name": "Placentalia"}, {"depth": 20, "id": "9347", "name": "eutherian mammals"}, {"depth": 20, "id": "9347", "name": "placental mammals"}, {"depth": 20, "id": "9347", "name": "placentals"}, {"depth": 21, "id": "1437010", "name": "Boreoeutheria"}, {"depth": 21, "id": "1437010", "name": "Boreotheria"}, {"depth": 22, "id": "314146", "name": "Euarchontoglires"}, {"depth": 23, "id": "9443", "name": "Primates"}, {"depth": 23, "id": "9443", "name": "Primata"}, {"depth": 23, "id": "9443", "name": "primate"}, {"depth": 23, "id": "9443", "name": "primates"}, {"depth": 24, "id": "376913", "name": "Haplorrhini"}, {"depth": 25, "id": "314293", "name": "Simiiformes"}, {"depth": 25, "id": "314293", "name": "Anthropoidea"}, {"depth": 26, "id": "9526", "name": "Catarrhini"}, {"depth": 27, "id": "314295", "name": "Hominoidea"}, {"depth": 27, "id": "314295", "name": "ape"}, {"depth": 27, "id": "314295", "name": "apes"}, {"depth": 28, "id": "9604", "name": "Hominidae"}, {"depth": 28, "id": "9604", "name": "Pongidae"}, {"depth": 28, "id": "9604", "name": "great apes"}, {"depth": 29, "id": "207598", "name": "Homininae"}, {"depth": 29, "id": "207598", "name": "Homo/Pan/Gorilla group"}, {"depth": 30, "id": "9605", "name": "Homo"}, {"depth": 30, "id": "9605", "name": "humans"}, {"depth": 31, "id": "9606", "name": "Homo sapiens"}, {"depth": 31, "id": "9606", "name": "human"}]}], "rcsb_genomic_lineage": [{"depth": 2, "id": "9606:10:aldo_keto_reductase_family_1_member_c1", "name": "aldo-keto reductase family 1 member C1"}, {"depth": 1, "id": "9606:10", "name": "Chromosome 10"}, {"depth": 0, "id": "9606", "name": "Homo sapiens"}], "rcsb_polymer_entity": {"formula_weight": 36.836, "pdbx_description": "Aldo-keto reductase family 1 member C1", "pdbx_ec": "1.1.1.149", "pdbx_number_of_molecules": 1, "rcsb_multiple_source_flag": "N", "rcsb_source_part_count": 1, "rcsb_source_taxonomy_count": 1, "src_method": "man", "rcsb_ec_lineage": [{"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.1.1.149", "name": "20alpha-hydroxysteroid dehydrogenase"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.1.1.53", "name": "3alpha(or 20beta)-hydroxysteroid dehydrogenase"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.1.1.209", "name": "3(or 17)alpha-hydroxysteroid dehydrogenase"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.3", "name": "Acting on the CH-CH group of donors"}, {"depth": 3, "id": "1.3.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.3.1.20", "name": "trans-1,2-dihydrobenzene-1,2-diol dehydrogenase"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.1.1.51", "name": "3(or 17)beta-hydroxysteroid dehydrogenase"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.1.1.62", "name": "17beta-estradiol 17-dehydrogenase"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.1.1.357", "name": "3alpha-hydroxysteroid 3-dehydrogenase"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.1.1.210", "name": "3beta(or 20alpha)-hydroxysteroid dehydrogenase"}, {"depth": 1, "id": "1", "name": "Oxidoreductases"}, {"depth": 2, "id": "1.1", "name": "Acting on the CH-OH group of donors"}, {"depth": 3, "id": "1.1.1", "name": "With NAD+ or NADP+ as acceptor"}, {"depth": 4, "id": "1.1.1.112", "name": "indanol dehydrogenase"}], "rcsb_macromolecular_names_combined": [{"name": "Aldo-keto reductase family 1 member C1", "provenance_code": "ECO:0000304", "provenance_source": "PDB Preferred Name"}, {"name": "20alpha-hydroxysteroid dehydrogenase", "provenance_code": "ECO:0000303", "provenance_source": "PDB Synonym"}, {"name": "Trans-1,2- dihydrobenzene-1,2-diol dehydrogenase", "provenance_code": "ECO:0000303", "provenance_source": "PDB Synonym"}, {"name": "High-affinity hepatic bile acid-binding protein", "provenance_code": "ECO:0000303", "provenance_source": "PDB Synonym"}, {"name": "HBAB", "provenance_code": "ECO:0000303", "provenance_source": "PDB Synonym"}, {"name": "Chlordecone reductase homolog HAKRC", "provenance_code": "ECO:0000303", "provenance_source": "PDB Synonym"}, {"name": "Dihydrodiol dehydrogenase 2", "provenance_code": "ECO:0000303", "provenance_source": "PDB Synonym"}, {"name": "DD2", "provenance_code": "ECO:0000303", "provenance_source": "PDB Synonym"}], "rcsb_enzyme_class_combined": [{"depth": 4, "ec": "1.1.1.149", "provenance_source": "PDB Primary Data"}, {"depth": 4, "ec": "1.1.1.53", "provenance_source": "UniProt"}, {"depth": 4, "ec": "1.1.1.209", "provenance_source": "UniProt"}, {"depth": 4, "ec": "1.3.1.20", "provenance_source": "UniProt"}, {"depth": 4, "ec": "1.1.1.51", "provenance_source": "UniProt"}, {"depth": 4, "ec": "1.1.1.62", "provenance_source": "UniProt"}, {"depth": 4, "ec": "1.1.1.357", "provenance_source": "UniProt"}, {"depth": 3, "ec": "1.1.1", "provenance_source": "UniProt"}, {"depth": 4, "ec": "1.1.1.210", "provenance_source": "UniProt"}, {"depth": 4, "ec": "1.1.1.112", "provenance_source": "UniProt"}], "rcsb_polymer_name_combined": {"names": ["Aldo-keto reductase family 1 member C1"], "provenance_source": "UniProt Name"}}, "rcsb_polymer_entity_align": [{"provenance_source": "SIFTS", "reference_database_accession": "Q04828", "reference_database_name": "UniProt", "aligned_regions": [{"entity_beg_seq_id": 2, "length": 322, "ref_beg_seq_id": 2}]}], "rcsb_polymer_entity_annotation": [{"annotation_id": "PF00248", "assignment_version": "34.0", "name": "Aldo/keto reductase family (Aldo_ket_red)", "provenance_source": "Pfam", "type": "Pfam"}, {"annotation_id": "GO:0047115", "name": "trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016628", "name": "oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0047115", "name": "trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity"}, {"id": "GO:0016627", "name": "oxidoreductase activity, acting on the CH-CH group of donors"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0042448", "name": "progesterone metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0042180", "name": "ketone metabolic process"}, {"id": "GO:0010817", "name": "regulation of hormone levels"}, {"id": "GO:0008202", "name": "steroid metabolic process"}, {"id": "GO:0065007", "name": "biological regulation"}, {"id": "GO:0044238", "name": "primary metabolic process"}, {"id": "GO:0008207", "name": "C21-steroid hormone metabolic process"}, {"id": "GO:0042445", "name": "hormone metabolic process"}, {"id": "GO:0042448", "name": "progesterone metabolic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0120254", "name": "olefinic compound metabolic process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0065008", "name": "regulation of biological quality"}, {"id": "GO:0006629", "name": "lipid metabolic process"}]}, {"annotation_id": "GO:0032052", "name": "bile acid binding", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0032052", "name": "bile acid binding"}, {"id": "GO:0043177", "name": "organic acid binding"}, {"id": "GO:0005488", "name": "binding"}, {"id": "GO:0043167", "name": "ion binding"}, {"id": "GO:0043168", "name": "anion binding"}, {"id": "GO:0031406", "name": "carboxylic acid binding"}, {"id": "GO:0003674", "name": "molecular_function"}, {"id": "GO:0033293", "name": "monocarboxylic acid binding"}, {"id": "GO:0036094", "name": "small molecule binding"}]}, {"annotation_id": "GO:0047045", "name": "testosterone 17-beta-dehydrogenase (NADP+) activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016229", "name": "steroid dehydrogenase activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0047045", "name": "testosterone dehydrogenase (NADP+) activity"}, {"id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0072582", "name": "17-beta-hydroxysteroid dehydrogenase (NADP+) activity"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0047006", "name": "17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase [NAD(P)+] activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016229", "name": "steroid dehydrogenase activity"}, {"id": "GO:0047006", "name": "17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase [NAD(P)+] activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0047718", "name": "indanol dehydrogenase activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0047718", "name": "indanol dehydrogenase activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0044597", "name": "daunorubicin metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0044597", "name": "daunorubicin metabolic process"}, {"id": "GO:0042180", "name": "ketone metabolic process"}, {"id": "GO:0030638", "name": "polyketide metabolic process"}, {"id": "GO:0016137", "name": "glycoside metabolic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:1901135", "name": "carbohydrate derivative metabolic process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0019748", "name": "secondary metabolic process"}]}, {"annotation_id": "GO:0008206", "name": "bile acid metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0043436", "name": "oxoacid metabolic process"}, {"id": "GO:0008202", "name": "steroid metabolic process"}, {"id": "GO:0019752", "name": "carboxylic acid metabolic process"}, {"id": "GO:0044238", "name": "primary metabolic process"}, {"id": "GO:0006082", "name": "organic acid metabolic process"}, {"id": "GO:0008206", "name": "bile acid metabolic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0044281", "name": "small molecule metabolic process"}, {"id": "GO:0032787", "name": "monocarboxylic acid metabolic process"}, {"id": "GO:0006629", "name": "lipid metabolic process"}]}, {"annotation_id": "GO:0042574", "name": "retinal metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016101", "name": "diterpenoid metabolic process"}, {"id": "GO:0042574", "name": "retinal metabolic process"}, {"id": "GO:0044238", "name": "primary metabolic process"}, {"id": "GO:0006081", "name": "aldehyde metabolic process"}, {"id": "GO:0001523", "name": "retinoid metabolic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0120254", "name": "olefinic compound metabolic process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0006721", "name": "terpenoid metabolic process"}, {"id": "GO:0006720", "name": "isoprenoid metabolic process"}, {"id": "GO:0006629", "name": "lipid metabolic process"}]}, {"annotation_id": "GO:0070062", "name": "extracellular exosome", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0070062", "name": "extracellular exosome"}, {"id": "GO:0043227", "name": "membrane-bounded organelle"}, {"id": "GO:1903561", "name": "extracellular vesicle"}, {"id": "GO:0110165", "name": "cellular anatomical structure"}, {"id": "GO:0005575", "name": "cellular_component"}, {"id": "GO:0043230", "name": "extracellular organelle"}, {"id": "GO:0005576", "name": "extracellular region"}, {"id": "GO:0043226", "name": "organelle"}, {"id": "GO:0005615", "name": "extracellular space"}, {"id": "GO:0031982", "name": "vesicle"}, {"id": "GO:0065010", "name": "extracellular membrane-bounded organelle"}]}, {"annotation_id": "GO:0047024", "name": "5-alpha-androstane-3-beta,17-beta-diol dehydrogenase (NADP+) activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016229", "name": "steroid dehydrogenase activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0047024", "name": "5-alpha-androstane-3-beta,17-beta-diol dehydrogenase (NADP+) activity"}, {"id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "IPR020471", "name": "Aldo-keto reductase", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"depth": 1, "id": "IPR020471", "name": "Aldo-keto reductase"}]}, {"annotation_id": "IPR044482", "name": "Aldo-keto reductase family 1 member C", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"depth": 2, "id": "IPR044482", "name": "Aldo-keto reductase family 1 member C"}, {"depth": 1, "id": "IPR020471", "name": "Aldo-keto reductase"}]}, {"annotation_id": "GO:0005829", "name": "cytosol", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0110165", "name": "cellular anatomical structure"}, {"id": "GO:0005575", "name": "cellular_component"}, {"id": "GO:0005622", "name": "intracellular anatomical structure"}, {"id": "GO:0005737", "name": "cytoplasm"}, {"id": "GO:0005829", "name": "cytosol"}]}, {"annotation_id": "GO:0004032", "name": "aldose reductase (NADPH) activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0018455", "name": "alcohol dehydrogenase [NAD(P)+] activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0008106", "name": "alcohol dehydrogenase (NADP+) activity"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}, {"id": "GO:0004032", "name": "aldose reductase (NADPH) activity"}]}, {"annotation_id": "GO:0006693", "name": "prostaglandin metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0006693", "name": "prostaglandin metabolic process"}, {"id": "GO:0006690", "name": "icosanoid metabolic process"}, {"id": "GO:0006631", "name": "fatty acid metabolic process"}, {"id": "GO:0033559", "name": "unsaturated fatty acid metabolic process"}, {"id": "GO:0043436", "name": "oxoacid metabolic process"}, {"id": "GO:0019752", "name": "carboxylic acid metabolic process"}, {"id": "GO:0044238", "name": "primary metabolic process"}, {"id": "GO:0006082", "name": "organic acid metabolic process"}, {"id": "GO:0006692", "name": "prostanoid metabolic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0044281", "name": "small molecule metabolic process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0032787", "name": "monocarboxylic acid metabolic process"}, {"id": "GO:0006629", "name": "lipid metabolic process"}]}, {"annotation_id": "GO:0071395", "name": "cellular response to jasmonic acid stimulus", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0051716", "name": "cellular response to stimulus"}, {"id": "GO:0033993", "name": "response to lipid"}, {"id": "GO:0050896", "name": "response to stimulus"}, {"id": "GO:0009753", "name": "response to jasmonic acid"}, {"id": "GO:0070542", "name": "response to fatty acid"}, {"id": "GO:0009719", "name": "response to endogenous stimulus"}, {"id": "GO:1901700", "name": "response to oxygen-containing compound"}, {"id": "GO:1901701", "name": "cellular response to oxygen-containing compound"}, {"id": "GO:0071398", "name": "cellular response to fatty acid"}, {"id": "GO:0071495", "name": "cellular response to endogenous stimulus"}, {"id": "GO:0070887", "name": "cellular response to chemical stimulus"}, {"id": "GO:0071395", "name": "cellular response to jasmonic acid stimulus"}, {"id": "GO:0009725", "name": "response to hormone"}, {"id": "GO:0042221", "name": "response to chemical"}, {"id": "GO:0071396", "name": "cellular response to lipid"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0032870", "name": "cellular response to hormone stimulus"}]}, {"annotation_id": "GO:0030855", "name": "epithelial cell differentiation", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0032502", "name": "developmental process"}, {"id": "GO:0060429", "name": "epithelium development"}, {"id": "GO:0048869", "name": "cellular developmental process"}, {"id": "GO:0030154", "name": "cell differentiation"}, {"id": "GO:0048856", "name": "anatomical structure development"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0009888", "name": "tissue development"}, {"id": "GO:0030855", "name": "epithelial cell differentiation"}]}, {"annotation_id": "GO:0042632", "name": "cholesterol homeostasis", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0055092", "name": "sterol homeostasis"}, {"id": "GO:0048878", "name": "chemical homeostasis"}, {"id": "GO:0042592", "name": "homeostatic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0042632", "name": "cholesterol homeostasis"}, {"id": "GO:0055088", "name": "lipid homeostasis"}]}, {"annotation_id": "GO:0015721", "name": "bile acid and bile salt transport", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0015711", "name": "organic anion transport"}, {"id": "GO:0046942", "name": "carboxylic acid transport"}, {"id": "GO:0006810", "name": "transport"}, {"id": "GO:0010876", "name": "lipid localization"}, {"id": "GO:0015721", "name": "bile acid and bile salt transport"}, {"id": "GO:0006869", "name": "lipid transport"}, {"id": "GO:0015850", "name": "organic hydroxy compound transport"}, {"id": "GO:0051234", "name": "establishment of localization"}, {"id": "GO:0015849", "name": "organic acid transport"}, {"id": "GO:0051179", "name": "localization"}, {"id": "GO:0015718", "name": "monocarboxylic acid transport"}, {"id": "GO:0033036", "name": "macromolecule localization"}, {"id": "GO:0008150", "name": "biological_process"}]}, {"annotation_id": "GO:0047042", "name": "androsterone dehydrogenase (B-specific) activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0047042", "name": "androsterone dehydrogenase (B-specific) activity"}]}, {"annotation_id": "GO:0047086", "name": "ketosteroid monooxygenase activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0004497", "name": "monooxygenase activity"}, {"id": "GO:0016705", "name": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen"}, {"id": "GO:0047086", "name": "ketosteroid monooxygenase activity"}, {"id": "GO:0016709", "name": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0031406", "name": "carboxylic acid binding", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0043177", "name": "organic acid binding"}, {"id": "GO:0005488", "name": "binding"}, {"id": "GO:0043167", "name": "ion binding"}, {"id": "GO:0043168", "name": "anion binding"}, {"id": "GO:0031406", "name": "carboxylic acid binding"}, {"id": "GO:0003674", "name": "molecular_function"}, {"id": "GO:0036094", "name": "small molecule binding"}]}, {"annotation_id": "GO:0016655", "name": "oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016651", "name": "oxidoreductase activity, acting on NAD(P)H"}, {"id": "GO:0016655", "name": "oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:2000379", "name": "positive regulation of reactive oxygen species metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0050789", "name": "regulation of biological process"}, {"id": "GO:0050794", "name": "regulation of cellular process"}, {"id": "GO:0072593", "name": "reactive oxygen species metabolic process"}, {"id": "GO:0065007", "name": "biological regulation"}, {"id": "GO:0048518", "name": "positive regulation of biological process"}, {"id": "GO:2000379", "name": "positive regulation of reactive oxygen species metabolic process"}, {"id": "GO:0009893", "name": "positive regulation of metabolic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0019222", "name": "regulation of metabolic process"}, {"id": "GO:0048522", "name": "positive regulation of cellular process"}, {"id": "GO:2000377", "name": "regulation of reactive oxygen species metabolic process"}]}, {"annotation_id": "IPR018170", "name": "Aldo/keto reductase, conserved site", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"id": "IPR018170", "name": "Aldo/keto reductase, conserved site"}]}, {"annotation_id": "GO:0004033", "name": "aldo-keto reductase (NADPH) activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0004033", "name": "aldo-keto reductase (NADPH) activity"}]}, {"annotation_id": "GO:0006805", "name": "xenobiotic metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0051716", "name": "cellular response to stimulus"}, {"id": "GO:0070887", "name": "cellular response to chemical stimulus"}, {"id": "GO:0050896", "name": "response to stimulus"}, {"id": "GO:0042221", "name": "response to chemical"}, {"id": "GO:0071466", "name": "cellular response to xenobiotic stimulus"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0006805", "name": "xenobiotic metabolic process"}, {"id": "GO:0009410", "name": "response to xenobiotic stimulus"}]}, {"annotation_id": "GO:0047044", "name": "androstan-3-alpha,17-beta-diol dehydrogenase (NAD+) activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016229", "name": "steroid dehydrogenase activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0047044", "name": "androstan-3-alpha,17-beta-diol dehydrogenase (NAD+) activity"}, {"id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0030299", "name": "intestinal cholesterol absorption", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0098856", "name": "intestinal lipid absorption"}, {"id": "GO:0032501", "name": "multicellular organismal process"}, {"id": "GO:0007586", "name": "digestion"}, {"id": "GO:0003008", "name": "system process"}, {"id": "GO:0050892", "name": "intestinal absorption"}, {"id": "GO:0022600", "name": "digestive system process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0030299", "name": "intestinal cholesterol absorption"}, {"id": "GO:0044241", "name": "lipid digestion"}]}, {"annotation_id": "GO:0047023", "name": "androsterone dehydrogenase [NAD(P)+] activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016229", "name": "steroid dehydrogenase activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0047023", "name": "androsterone dehydrogenase [NAD(P)+] activity"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "IPR023210", "name": "NADP-dependent oxidoreductase domain", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"id": "IPR023210", "name": "NADP-dependent oxidoreductase domain"}]}, {"annotation_id": "GO:0044598", "name": "doxorubicin metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0042180", "name": "ketone metabolic process"}, {"id": "GO:0030638", "name": "polyketide metabolic process"}, {"id": "GO:0016137", "name": "glycoside metabolic process"}, {"id": "GO:1901135", "name": "carbohydrate derivative metabolic process"}, {"id": "GO:0006066", "name": "alcohol metabolic process"}, {"id": "GO:0044598", "name": "doxorubicin metabolic process"}, {"id": "GO:0019748", "name": "secondary metabolic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0044281", "name": "small molecule metabolic process"}, {"id": "GO:1902644", "name": "tertiary alcohol metabolic process"}, {"id": "GO:0034308", "name": "primary alcohol metabolic process"}]}, {"annotation_id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016229", "name": "steroid dehydrogenase activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "IPR036812", "name": "NAD(P)-dependent oxidoreductase domain superfamily", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"id": "IPR036812", "name": "NAD(P)-dependent oxidoreductase domain superfamily"}]}, {"annotation_id": "GO:0004303", "name": "estradiol 17-beta-dehydrogenase [NAD(P)+] activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016229", "name": "steroid dehydrogenase activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0004303", "name": "estradiol 17-beta-dehydrogenase [NAD(P)+] activity"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0001523", "name": "retinoid metabolic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016101", "name": "diterpenoid metabolic process"}, {"id": "GO:0001523", "name": "retinoid metabolic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0044238", "name": "primary metabolic process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0006721", "name": "terpenoid metabolic process"}, {"id": "GO:0006720", "name": "isoprenoid metabolic process"}, {"id": "GO:0006629", "name": "lipid metabolic process"}]}, {"annotation_id": "GO:0033703", "name": "3-beta-hydroxy-5-beta-steroid dehydrogenase (NADP+) activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0016229", "name": "steroid dehydrogenase activity"}, {"id": "GO:0033703", "name": "3-beta-hydroxy-5-beta-steroid dehydrogenase (NADP+) activity"}, {"id": "GO:0016491", "name": "oxidoreductase activity"}, {"id": "GO:0016616", "name": "oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0016614", "name": "oxidoreductase activity, acting on CH-OH group of donors"}, {"id": "GO:0033764", "name": "steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0007586", "name": "digestion", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0032501", "name": "multicellular organismal process"}, {"id": "GO:0007586", "name": "digestion"}, {"id": "GO:0008150", "name": "biological_process"}]}], "rcsb_polymer_entity_container_identifiers": {"asym_ids": ["A"], "auth_asym_ids": ["A"], "chem_comp_monomers": ["ALA", "ARG", "ASN", "ASP", "CYS", "GLN", "GLU", "GLY", "HIS", "ILE", "LEU", "LYS", "MET", "PHE", "PRO", "SER", "THR", "TRP", "TYR", "VAL"], "entity_id": "1", "entry_id": "1MRQ", "rcsb_id": "1MRQ_1", "uniprot_ids": ["Q04828"], "reference_sequence_identifiers": [{"database_accession": "Q04828", "database_name": "UniProt", "entity_sequence_coverage": 0.9969040247678018, "provenance_source": "SIFTS", "reference_sequence_coverage": 0.9969040247678018}]}, "rcsb_polymer_entity_feature": [{"assignment_version": "34.0", "feature_id": "PF00248", "name": "Aldo/keto reductase family (Aldo_ket_red)", "provenance_source": "Pfam", "type": "Pfam", "feature_positions": [{"beg_seq_id": 18, "end_seq_id": 301}]}, {"assignment_version": "V1.0", "feature_id": "range_feature_1", "name": "cloning artifact", "provenance_source": "PDB", "type": "artifact", "feature_positions": [{"beg_seq_id": 1, "end_seq_id": 1}]}, {"name": "Hydropathy values", "provenance_source": "biojava-7.2.4", "type": "hydropathy", "feature_positions": [{"beg_seq_id": 5, "values": [-1.52, -0.71, -0.71, -1.01, -0.62, -0.83, -0.13, -0.2, -0.84, 0.06, 0.06, 0.4, 1.1, 1.1, 1.38, 0.92, 0.91, 0.91, 0.64, -0.17, 0.34, -0.14, -0.53, -0.54, -0.83, -0.83, -0.23, -0.82, -0.23, -0.78, -1.03, -0.18, 0.11, 1.04, 0.46, 0.23, 0.58, 0.69, 0.27, 0.34, 0.42, -0.17, -0.76, -0.17, -0.72, -0.26, -0.71, -0.6, -0.63, -1.52, -1.52, -1.82, -1.56, -1.24, -1.24, -0.9, -0.01, -0.12, 0.18, 0.13, 1.02, 0.76, 0.41, -0.06, -0.34, -0.38, -0.31, -0.72, -0.68, -1.57, -1.27, -0.57, -0.67, -0.66, -1.21, -1.21, -0.29, 0.0, 0.67, -0.22, -0.62, -0.83, -1.26, -1.34, -1.3, -1.3, -0.73, -1.51, -1.3, -1.01, -0.23, -0.12, -0.44, -0.14, -0.14, -1.04, -0.93, -0.33, -0.92, -0.92, -0.92, -0.57, -0.01, -0.82, 0.03, 0.28, 0.28, 1.17, 0.39, 1.09, 1.06, 1.06, 1.36, 1.4, 1.11, 0.51, -0.03, -0.07, -0.77, -0.12, -0.09, -0.18, -1.08, -1.03, -1.24, -1.59, -1.24, -1.29, -1.26, -1.33, -0.84, -0.8, -0.49, 0.37, 0.37, 0.83, 1.54, 1.24, 0.74, 0.33, 0.33, 0.61, 0.61, 0.61, -0.24, -0.24, -0.88, -1.19, -0.89, -0.54, -0.32, -0.59, -0.63, -0.29, -0.07, 0.32, 1.18, 0.89, 0.54, 0.43, -0.16, -0.22, -0.63, -1.52, -1.06, -1.91, -1.61, -0.72, -0.61, -0.61, -0.54, -0.22, 0.12, 0.12, 0.08, -0.28, -1.21, -1.81, -0.96, -0.24, -0.46, -0.8, -0.76, -0.71, -0.29, -0.21, -0.21, -0.82, -0.79, -0.79, -0.79, -1.76, -1.8, -1.66, -0.88, -1.09, -0.63, -0.67, -0.71, -0.41, -0.34, -0.3, -0.22, -0.18, 0.63, 0.79, 0.71, 1.0, 1.0, 1.63, 2.44, 1.9, 1.34, 0.57, -0.4, -0.99, -1.23, -1.32, -1.62, -1.58, -1.92, -2.01, -2.04, -1.63, -1.42, -0.57, 0.03, 0.56, -0.3, -0.3, -0.3, 0.56, 1.07, 1.52, 1.26, 1.26, 1.03, 0.99, 0.94, 0.77, -0.13, -1.06, -1.41, -1.79, -2.01, -1.79, -0.86, -0.22, 0.56, 0.49, 0.84, 0.53, 1.13, 0.54, -0.38, -0.92, -0.66, -0.61, 0.36, 0.92, 1.51, 0.66, 0.96, 1.31, 0.97, 0.11, -0.74, -1.71, -1.63, -2.33, -2.29, -2.59, -1.98, -1.98, -1.12, -0.42, -0.31, -0.5, -0.39, 0.42, 0.73, 0.18, 0.18, -0.68, -0.78, -0.82, -0.93, -0.04, -0.86, -0.82, -0.31, -0.31, -0.42, -1.02, -0.12, -0.82, -1.47, -0.66, -0.69, -0.69, -0.69, 0.31, 1.01, 0.74, 1.2, 1.17, 0.57, 0.26, -0.31, -0.1, -0.29, -0.69, -1.28, -1.62, -1.59]}]}, {"name": "Disordered regions", "provenance_source": "IUPred2(short)", "type": "disorder", "feature_positions": [{"beg_seq_id": 1, "values": [0.84, 0.82, 0.77, 0.74, 0.63, 0.56, 0.55, 0.45, 0.34, 0.3, 0.17, 0.16, 0.15, 0.09, 0.08, 0.15, 0.11, 0.17, 0.16, 0.19, 0.25, 0.25, 0.23, 0.21, 0.15, 0.23, 0.23, 0.2, 0.26, 0.24, 0.22, 0.22, 0.24, 0.21, 0.29, 0.23, 0.21, 0.26, 0.17, 0.24, 0.21, 0.19, 0.2, 0.15, 0.12, 0.17, 0.15, 0.18, 0.19, 0.21, 0.22, 0.25, 0.25, 0.21, 0.17, 0.17, 0.24, 0.23, 0.16, 0.2, 0.2, 0.2, 0.23, 0.16, 0.21, 0.28, 0.28, 0.29, 0.2, 0.13, 0.09, 0.13, 0.13, 0.19, 0.15, 0.14, 0.11, 0.11, 0.11, 0.15, 0.17, 0.19, 0.19, 0.12, 0.12, 0.12, 0.13, 0.11, 0.06, 0.1, 0.15, 0.2, 0.13, 0.12, 0.13, 0.12, 0.22, 0.19, 0.2, 0.14, 0.11, 0.12, 0.06, 0.04, 0.05, 0.04, 0.04, 0.02, 0.03, 0.03, 0.03, 0.02, 0.02, 0.05, 0.05, 0.05, 0.09, 0.05, 0.05, 0.06, 0.08, 0.13, 0.13, 0.18, 0.25, 0.31, 0.32, 0.25, 0.26, 0.24, 0.31, 0.24, 0.32, 0.27, 0.17, 0.15, 0.14, 0.09, 0.14, 0.18, 0.12, 0.14, 0.13, 0.07, 0.07, 0.07, 0.06, 0.1, 0.1, 0.13, 0.12, 0.12, 0.11, 0.1, 0.1, 0.16, 0.18, 0.12, 0.16, 0.15, 0.17, 0.23, 0.16, 0.16, 0.2, 0.15, 0.11, 0.13, 0.13, 0.23, 0.26, 0.18, 0.19, 0.19, 0.2, 0.29, 0.22, 0.13, 0.2, 0.21, 0.15, 0.15, 0.07, 0.11, 0.13, 0.1, 0.08, 0.12, 0.12, 0.12, 0.1, 0.06, 0.07, 0.07, 0.06, 0.03, 0.02, 0.04, 0.07, 0.08, 0.05, 0.05, 0.03, 0.05, 0.04, 0.02, 0.04, 0.06, 0.03, 0.03, 0.03, 0.03, 0.05, 0.07, 0.07, 0.14, 0.16, 0.12, 0.12, 0.13, 0.13, 0.18, 0.26, 0.27, 0.25, 0.19, 0.27, 0.27, 0.33, 0.35, 0.28, 0.22, 0.2, 0.14, 0.12, 0.12, 0.11, 0.17, 0.22, 0.21, 0.19, 0.21, 0.18, 0.11, 0.1, 0.12, 0.13, 0.13, 0.07, 0.06, 0.05, 0.08, 0.12, 0.13, 0.14, 0.11, 0.07, 0.04, 0.03, 0.04, 0.04, 0.02, 0.02, 0.03, 0.04, 0.07, 0.05, 0.08, 0.08, 0.13, 0.08, 0.14, 0.1, 0.05, 0.05, 0.05, 0.08, 0.07, 0.11, 0.13, 0.13, 0.13, 0.16, 0.15, 0.12, 0.08, 0.09, 0.16, 0.1, 0.11, 0.1, 0.15, 0.1, 0.14, 0.16, 0.1, 0.17, 0.11, 0.19, 0.13, 0.08, 0.06, 0.06, 0.1, 0.12, 0.14, 0.14, 0.15, 0.09, 0.14, 0.15, 0.16, 0.11, 0.2, 0.24, 0.36, 0.48, 0.53, 0.64, 0.67, 0.77, 0.87, 0.92]}]}, {"name": "Disordered binding sites", "provenance_source": "Anchor2", "type": "disorder_binding", "feature_positions": [{"beg_seq_id": 1, "values": [0.23, 0.23, 0.23, 0.24, 0.25, 0.26, 0.27, 0.29, 0.31, 0.34, 0.36, 0.38, 0.41, 0.43, 0.41, 0.4, 0.39, 0.39, 0.39, 0.41, 0.42, 0.42, 0.4, 0.38, 0.36, 0.35, 0.34, 0.33, 0.32, 0.31, 0.31, 0.31, 0.31, 0.32, 0.32, 0.32, 0.32, 0.32, 0.32, 0.33, 0.32, 0.32, 0.32, 0.32, 0.32, 0.33, 0.33, 0.33, 0.33, 0.33, 0.33, 0.33, 0.34, 0.34, 0.34, 0.34, 0.34, 0.35, 0.35, 0.36, 0.37, 0.37, 0.37, 0.36, 0.35, 0.33, 0.32, 0.31, 0.3, 0.28, 0.27, 0.26, 0.25, 0.24, 0.23, 0.23, 0.24, 0.25, 0.25, 0.26, 0.27, 0.27, 0.28, 0.28, 0.29, 0.29, 0.29, 0.29, 0.29, 0.28, 0.27, 0.27, 0.27, 0.27, 0.26, 0.25, 0.25, 0.24, 0.24, 0.23, 0.23, 0.24, 0.24, 0.25, 0.26, 0.28, 0.29, 0.32, 0.33, 0.35, 0.37, 0.38, 0.39, 0.4, 0.39, 0.37, 0.34, 0.32, 0.3, 0.28, 0.26, 0.24, 0.22, 0.21, 0.2, 0.19, 0.19, 0.19, 0.19, 0.19, 0.19, 0.2, 0.2, 0.21, 0.22, 0.23, 0.25, 0.27, 0.28, 0.29, 0.3, 0.31, 0.31, 0.3, 0.29, 0.28, 0.27, 0.26, 0.23, 0.22, 0.21, 0.2, 0.19, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.24, 0.25, 0.25, 0.25, 0.25, 0.25, 0.24, 0.24, 0.22, 0.21, 0.21, 0.21, 0.21, 0.21, 0.21, 0.21, 0.2, 0.19, 0.17, 0.16, 0.15, 0.15, 0.13, 0.12, 0.1, 0.09, 0.09, 0.08, 0.08, 0.09, 0.09, 0.09, 0.1, 0.12, 0.15, 0.17, 0.19, 0.2, 0.22, 0.23, 0.24, 0.25, 0.27, 0.27, 0.26, 0.25, 0.26, 0.27, 0.3, 0.32, 0.34, 0.36, 0.37, 0.36, 0.36, 0.35, 0.35, 0.33, 0.32, 0.29, 0.27, 0.25, 0.23, 0.21, 0.21, 0.21, 0.22, 0.21, 0.21, 0.21, 0.21, 0.22, 0.22, 0.23, 0.24, 0.24, 0.24, 0.25, 0.26, 0.26, 0.27, 0.28, 0.28, 0.29, 0.29, 0.3, 0.31, 0.33, 0.33, 0.34, 0.35, 0.35, 0.36, 0.36, 0.36, 0.35, 0.34, 0.33, 0.32, 0.3, 0.29, 0.28, 0.27, 0.26, 0.25, 0.25, 0.24, 0.24, 0.23, 0.22, 0.21, 0.2, 0.19, 0.17, 0.16, 0.16, 0.16, 0.16, 0.16, 0.16, 0.17, 0.18, 0.19, 0.21, 0.21, 0.22, 0.22, 0.23, 0.23, 0.23, 0.23, 0.23, 0.23, 0.22, 0.22, 0.22, 0.23, 0.23, 0.24, 0.25, 0.27, 0.29, 0.32, 0.35, 0.38, 0.41, 0.43, 0.42, 0.39, 0.38, 0.36, 0.36, 0.36, 0.36, 0.36, 0.36, 0.36, 0.36, 0.36, 0.36, 0.37, 0.37, 0.36]}]}], "rcsb_polymer_entity_feature_summary": [{"count": 1, "coverage": 0.0031, "maximum_length": 1, "minimum_length": 1, "type": "artifact"}, {"count": 1, "coverage": 0.87926, "type": "Pfam"}], "rcsb_polymer_entity_group_membership": [{"aggregation_method": "sequence_identity", "group_id": "676_70", "similarity_cutoff": 70.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 2, "ref_beg_seq_id": 20}, {"entity_beg_seq_id": 3, "length": 321, "ref_beg_seq_id": 23}]}, {"aggregation_method": "sequence_identity", "group_id": "3157_95", "similarity_cutoff": 95.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 323, "ref_beg_seq_id": 16}]}, {"aggregation_method": "sequence_identity", "group_id": "239_50", "similarity_cutoff": 50.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 2, "ref_beg_seq_id": 39}, {"entity_beg_seq_id": 3, "length": 26, "ref_beg_seq_id": 42}, {"entity_beg_seq_id": 29, "length": 42, "ref_beg_seq_id": 69}, {"entity_beg_seq_id": 71, "length": 56, "ref_beg_seq_id": 113}, {"entity_beg_seq_id": 127, "length": 7, "ref_beg_seq_id": 188}, {"entity_beg_seq_id": 134, "length": 75, "ref_beg_seq_id": 196}, {"entity_beg_seq_id": 209, "length": 22, "ref_beg_seq_id": 272}, {"entity_beg_seq_id": 231, "length": 52, "ref_beg_seq_id": 298}, {"entity_beg_seq_id": 283, "length": 25, "ref_beg_seq_id": 351}, {"entity_beg_seq_id": 308, "length": 1, "ref_beg_seq_id": 385}, {"entity_beg_seq_id": 309, "length": 15, "ref_beg_seq_id": 387}]}, {"aggregation_method": "sequence_identity", "group_id": "12237_100", "similarity_cutoff": 100.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 323, "ref_beg_seq_id": 16}]}, {"aggregation_method": "matching_uniprot_accession", "group_id": "Q04828", "aligned_regions": [{"entity_beg_seq_id": 2, "length": 322, "ref_beg_seq_id": 2}]}, {"aggregation_method": "sequence_identity", "group_id": "259_30", "similarity_cutoff": 30.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 1, "ref_beg_seq_id": 59}, {"entity_beg_seq_id": 2, "length": 1, "ref_beg_seq_id": 74}, {"entity_beg_seq_id": 3, "length": 8, "ref_beg_seq_id": 77}, {"entity_beg_seq_id": 11, "length": 10, "ref_beg_seq_id": 86}, {"entity_beg_seq_id": 21, "length": 5, "ref_beg_seq_id": 97}, {"entity_beg_seq_id": 26, "length": 4, "ref_beg_seq_id": 105}, {"entity_beg_seq_id": 30, "length": 1, "ref_beg_seq_id": 115}, {"entity_beg_seq_id": 31, "length": 2, "ref_beg_seq_id": 118}, {"entity_beg_seq_id": 33, "length": 2, "ref_beg_seq_id": 132}, {"entity_beg_seq_id": 35, "length": 6, "ref_beg_seq_id": 135}, {"entity_beg_seq_id": 41, "length": 10, "ref_beg_seq_id": 143}, {"entity_beg_seq_id": 51, "length": 18, "ref_beg_seq_id": 155}, {"entity_beg_seq_id": 69, "length": 2, "ref_beg_seq_id": 174}, {"entity_beg_seq_id": 71, "length": 20, "ref_beg_seq_id": 183}, {"entity_beg_seq_id": 91, "length": 37, "ref_beg_seq_id": 210}, {"entity_beg_seq_id": 128, "length": 4, "ref_beg_seq_id": 266}, {"entity_beg_seq_id": 132, "length": 2, "ref_beg_seq_id": 274}, {"entity_beg_seq_id": 134, "length": 3, "ref_beg_seq_id": 277}, {"entity_beg_seq_id": 137, "length": 24, "ref_beg_seq_id": 284}, {"entity_beg_seq_id": 161, "length": 2, "ref_beg_seq_id": 334}, {"entity_beg_seq_id": 163, "length": 17, "ref_beg_seq_id": 343}, {"entity_beg_seq_id": 180, "length": 4, "ref_beg_seq_id": 363}, {"entity_beg_seq_id": 184, "length": 16, "ref_beg_seq_id": 368}, {"entity_beg_seq_id": 200, "length": 9, "ref_beg_seq_id": 386}, {"entity_beg_seq_id": 209, "length": 7, "ref_beg_seq_id": 396}, {"entity_beg_seq_id": 216, "length": 12, "ref_beg_seq_id": 422}, {"entity_beg_seq_id": 228, "length": 22, "ref_beg_seq_id": 445}, {"entity_beg_seq_id": 250, "length": 33, "ref_beg_seq_id": 473}, {"entity_beg_seq_id": 283, "length": 2, "ref_beg_seq_id": 507}, {"entity_beg_seq_id": 285, "length": 1, "ref_beg_seq_id": 511}, {"entity_beg_seq_id": 286, "length": 12, "ref_beg_seq_id": 513}, {"entity_beg_seq_id": 298, "length": 12, "ref_beg_seq_id": 528}, {"entity_beg_seq_id": 310, "length": 14, "ref_beg_seq_id": 556}]}, {"aggregation_method": "sequence_identity", "group_id": "3533_90", "similarity_cutoff": 90.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 323, "ref_beg_seq_id": 16}]}], "rcsb_polymer_entity_name_com": [{"name": "20alpha-hydroxysteroid dehydrogenase, \nTrans-1,2- dihydrobenzene-1,2-diol dehydrogenase,\nHigh-affinity hepatic bile acid-binding protein, HBAB,\nChlordecone reductase homolog HAKRC, \nDihydrodiol dehydrogenase 2, DD2"}], "rcsb_related_target_references": [{"related_resource_name": "ChEMBL", "related_resource_version": "36", "related_target_id": "CHEMBL5905", "target_taxonomy_id": 9606, "aligned_target": [{"entity_beg_seq_id": 2, "length": 321, "target_beg_seq_id": 2}]}, {"related_resource_name": "ChEMBL", "related_resource_version": "36", "related_target_id": "CHEMBL5847", "target_taxonomy_id": 9606, "aligned_target": [{"entity_beg_seq_id": 2, "length": 321, "target_beg_seq_id": 2}]}, {"related_resource_name": "DrugBank", "related_resource_version": "5.1", "related_target_id": "P52895", "target_taxonomy_id": 9606, "aligned_target": [{"entity_beg_seq_id": 2, "length": 321, "target_beg_seq_id": 2}]}, {"related_resource_name": "DrugBank", "related_resource_version": "5.1", "related_target_id": "Q04828", "target_taxonomy_id": 9606, "aligned_target": [{"entity_beg_seq_id": 2, "length": 321, "target_beg_seq_id": 2}]}, {"related_resource_name": "Pharos", "related_resource_version": "6.13.4", "related_target_id": "15823", "target_taxonomy_id": 9606, "aligned_target": [{"entity_beg_seq_id": 2, "length": 321, "target_beg_seq_id": 2}]}, {"related_resource_name": "Pharos", "related_resource_version": "6.13.4", "related_target_id": "15942", "target_taxonomy_id": 9606, "aligned_target": [{"entity_beg_seq_id": 2, "length": 321, "target_beg_seq_id": 2}]}], "rcsb_target_cofactors": [{"binding_assay_value": 2.92, "binding_assay_value_type": "pKi", "cofactor_in_ch_ikey": "VECNLFVATDBRIW-UHFFFAOYSA-N", "cofactor_smiles": "O=C(O)c1cc(-c2cccc(O)c2)nc2ccccc12", "cofactor_resource_id": "CHEMBL2172252", "neighbor_flag": "N", "resource_name": "ChEMBL", "resource_version": "36", "target_resource_id": "CHEMBL5847"}, {"binding_assay_value": 2.92, "binding_assay_value_type": "pKi", "cofactor_in_ch_ikey": "UKZSZLMBZKZOQQ-UHFFFAOYSA-N", "cofactor_smiles": "CN(c1ccc(C(=O)O)cc1)S(=O)(=O)c1ccccc1", "cofactor_resource_id": "CHEMBL1896308", "neighbor_flag": "N", "resource_name": "ChEMBL", "resource_version": "36", "target_resource_id": "CHEMBL5847"}, {"binding_assay_value": 2.9, "binding_assay_value_type": "pIC50", "cofactor_in_ch_ikey": "HZKNHDLUFBYIQN-VMPITWQZSA-N", "cofactor_smiles": "CC(C)=CCc1cc(/C=C/C(=O)O)ccc1O", "cofactor_name": "DRUPANIN", "cofactor_resource_id": "CHEMBL464997", "neighbor_flag": "N", "resource_name": "ChEMBL", "resource_version": "36", "target_resource_id": "CHEMBL5847"}, {"binding_assay_value": 2.86, "binding_assay_value_type": "pKi", "cofactor_in_ch_ikey": "OMIAELUTBHIIHL-UHFFFAOYSA-N", "cofactor_smiles": "O=C1COc2ccc(C(=O)c3ccccc3)cc2CN1", "cofactor_resource_id": "CHEMBL1414132", "neighbor_flag": "N", "resource_name": "ChEMBL", "resource_version": "36", "target_resource_id": "CHEMBL5847"}, {"binding_assay_value": 2.69, "binding_assay_value_type": "pIC50", "cofactor_in_ch_ikey": "QIQMFRHXYDLILE-UHFFFAOYSA-N", "cofactor_smiles": "O=C(CC1SC(=O)NC1=O)Nc1ccccc1O", "cofactor_resource_id": "CHEMBL2172258", "neighbor_flag": "N", "resource_name": "ChEMBL", "resource_version": "36", "target_resource_id": "CHEMBL5847"}, {"cofactor_in_ch_ikey": "BOPGDPNILDQYTO-NNYOXOHSSA-N", "cofactor_smiles": "NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O", "cofactor_chem_comp_id": "NAI", "cofactor_name": "NADH", "cofactor_resource_id": "DB00157", "mechanism_of_action": "NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.", "neighbor_flag": "N", "pubmed_ids": [12810547, 12416991], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "BLXXJMDCKKHMKV-UHFFFAOYSA-N", "cofactor_smiles": "COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2", "cofactor_chem_comp_id": "NBO", "cofactor_name": "Nabumetone", "cofactor_resource_id": "DB00461", "mechanism_of_action": "Nabumetone's active metabolite, 6-MNA, is an inhibitor of both COX-1 and COX-2 although it exhibits some COX-2 selectivity.[label,A178903] Inhibition of COX-1 and COX-2 reduces conversion of arachidonic acid to PGs and thromboxane (TXA<sub>2</sub>). This reduction in prostanoid production is the common mechanism that mediates the effects of nambutone.\r\n\r\nPGE<sub>2</sub> is the primary PG involved in modulation of nociception.[A179023] It mediates peripheral sensitization through a variety of effects.[T116,A179023] PGE<sub>2</sub> activates the G<sub>q</sub>-coupled EP<sub>1</sub> receptor leading to increased activity of the inositol trisphosphate/phospholipase C pathway. Activation of this pathway releases intracellular stores of calcium which directly reduces action potential threshold and activates protein kinase C (PKC) which contributes to several indirect mechanisms. PGE<sub>2</sub> also activates the EP<sub>4</sub> receptor, coupled to G<sub>s</sub>, which activates the adenylyl cyclase/protein kinase A (AC/PKA) signaling pathway. PKA and PKC both contribute to the potentiation of transient receptor potential cation channel subfamily V member 1 (TRPV1) potentiation, which increases sensitivity to heat stimuli. They also activate tetrodotoxin-resistant sodium channels and inhibit inward potassium currents. PKA further contributes to the activation of the P2X3 purine receptor and sensitization of T-type calcium channels. The activation and sensitization of depolarizing ion channels and inhibition of inward potassium currents serve to reduce the intensity of stimulus necessary to generate action potentials in nociceptive sensory afferents. PGE<sub>2</sub> act via EP<sub>3</sub> to increase sensitivity to bradykinin and via EP<sub>2</sub> to further increase heat sensitivity. Central sensitization occurs in the dorsal horn of the spinal cord and is mediated by the EP<sub>2</sub> receptor which couples to G<sub>s</sub>. Pre-synaptically, this receptor increases the release of pro-nociceptive neurotransmitters glutamate, CGRP, and substance P. Post-synaptically it increases the activity of AMPA and NMDA receptors and produces inhibition of inhibitory glycinergic neurons. Together these lead to a reduced threshold of activating, allowing low intensity stimuli to generate pain signals. PGI<sub>2</sub> is known to play a role via its G<sub>s</sub>-coupled IP receptor although the magnitude of its contribution varies. It has been proposed to be of greater importance in painful inflammatory conditions such as arthritis. By limiting sensitization, both peripheral and central, via these pathways NSAIDs can effectively reduce inflammatory pain.\r\n\r\nPGI<sub>2</sub> and PGE<sub>2</sub> contribute to acute inflammation via their IP and EP<sub>2</sub> receptors.[T116,A179044] Similarly to \u03b2 adrenergic receptors these are G<sub>s</sub>-coupled and mediate vasodilation through the AC/PKA pathway. PGE<sub>2</sub> also contributes by increasing leukocyte adhesion to the endothelium and attracts the cells to the site of injury.[T116] PGD<sub>2</sub> plays a role in the activation of endothelial cell release of cytokines through its DP<sub>1</sub> receptor.[A179044] PGI<sub>2</sub> and PGE<sub>2</sub> modulate T-helper cell activation and differentiation through IP, EP<sub>2</sub>, and EP<sub>4</sub> receptors which is believed to be an important activity in the pathology of arthritic conditions. By limiting the production of these PGs at the site of injury, NSAIDs can reduce inflammation.\r\n\r\nPGE<sub>2</sub> can cross the blood-brain barrier and act on excitatory G<sub>q</sub> EP<sub>3</sub> receptors on thermoregulatory neurons in the hypothalamus.[T116] This activation triggers an increase in heat-generation and a reduction in heat-loss to produce a fever. NSAIDs prevent the generation of PGE<sub>2</sub> thereby reducing the activity of these neurons.\r\n\r\nThe adverse effects of NSAIDs stem from the protective and regulatory roles of prostanoids which have been well-characterized.[T116] PGI<sub>2</sub> and PGE<sub>2</sub> regulate blood flow to the kidney by similar mechanisms to the vasodilation they produce in inflammation. Prevention of this regulation by NSAIDs produces vasoconstriction which limits renal function by reducing blood flow and the hydrostatic pressure which drives filtration. PGE<sub>2</sub> also regulates gastric protection via EP<sub>3</sub> receptors which are, in this location, coupled to G<sub>i</sub> which inhibits the AC/PKA pathway. This reduces the secretion of protons by H<sup>+</sup>/K<sup>+</sup> ATPase in parietal cells and increases the secretion of mucus and HCO<sub>3</sub><sup>-</sup> by superficial endothelial cells. Disruption of this protective action by NSAIDs lead to ulceration of the gastric mucosa. Lastly, disruption of PGI<sub>2</sub>, which opposes platelet aggregation, generation by COX-2 selective agents leads to an imbalance with TXA<sub>2</sub> generated by COX-1, which promotes aggregation of platelets, leading to increased risk of thrombosis. Since nabumetone is somewhat COX-2 selective it is thought to promote this imbalance and increase thrombotic risk.[A178903]", "neighbor_flag": "N", "pubmed_ids": [24659525], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "CTRLABGOLIVAIY-UHFFFAOYSA-N", "cofactor_smiles": "NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2", "cofactor_name": "Oxcarbazepine", "cofactor_resource_id": "DB00776", "mechanism_of_action": "The exact mechanism through which oxcarbazepine and its active metaoblite, MHD, exert their anti-epileptic effects is unclear, but is thought to primarily involve the blockade of voltage-gated sodium channels.[L8627,L8630,L8633,A186104] The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity. Both oxcarbazepine and MHD are thought to inhibit seizure activity by binding to the inactive state of voltage-gated sodium channels, thus prolonging the period in which the receptor is unavailable for action potential propagation.[A186101] This helps to stabilize hyperexcited neuronal membranes, inhibit repetitive neuron firing, and prevent the spread of seizure activity within the CNS without affecting normal neuronal transmission.[L8627,L8630,L8633]\r\n\r\nIncreased potassium conductance and modulation of voltage-activated calcium channels is also thought to play a role in the anti-seizure activity of oxcarbazepine.[L8627,L8630,L8633] Inhibition of glutamatergic activity was thought to contribute to oxcarbazepine's activity[A34516], but this effect could not be replicated _in vivo_.[A186104]", "neighbor_flag": "N", "pubmed_ids": [25063510], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "YMTINGFKWWXKFG-UHFFFAOYSA-N", "cofactor_smiles": "CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1", "cofactor_chem_comp_id": "J3O", "cofactor_name": "Fenofibrate", "cofactor_resource_id": "DB01039", "mechanism_of_action": "Fenofibrate activates peroxisome proliferator activated receptor alpha (PPAR\u03b1), increasing lipolysis, activating lipoprotein lipase, and reducing apoprotein C-III.[A186002,L8588,L8591] PPAR\u03b1 is a nuclear receptor and its activation alters lipid, glucose, and amino acid homeostasis.[A186002] Activation of PPAR\u03b1 activates transcription of gene transcription and translation that generates peroxisomes filled with hydrogen peroxide, reactive oxygen species, and hydroxyl radicals that also participate in lipolysis.[A186005] This mechanism of increased lipid metabolism is also associated with increased oxidative stress on the liver.[A186005] In rare cases this stress can lead to cirrhosis and chronic active hepatitis.[A186002,L8588,L8591]", "neighbor_flag": "N", "pubmed_ids": [27599626], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "RUDATBOHQWOJDD-UZVSRGJWSA-N", "cofactor_smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O", "cofactor_chem_comp_id": "IU5", "cofactor_name": "Ursodeoxycholic acid", "cofactor_resource_id": "DB01586", "mechanism_of_action": "Endogenous hydrophobic bile acids such as deoxycholic acid and chenodeoxycholic acid can exert hepatotoxic effects. Ursodeoxycholic acid is a hydrophilic bile acid that mediates its biological effects via several mechanisms. Ursodeoxycholic acid (UDCA) protects hepatocytes and cholangiocytes from bile acid-induced damage, such as reactive oxygen species (ROS)-induced inflammation and mitochondrial dysfunction.[A256267] UDCA was shown to reserve hepatocyte cell structures and stimulate anti-apoptotic pathways.[A256267,A256272,A256458,A256463] It was also shown to prevent the production of ROS by Kupffer cells and resident macrophages in the liver, thus attenuating oxidative stress in the liver.[A256267] \r\n\r\nUDCA can also change the hydrophobicity index of the bile acid pool: following oral administration, UDCA forms a major fraction of the human bile acid pool and competitively displaces the hydrophobic or more toxic bile acids.[A256272,A256267] It increases the absorption of hydrophilic bile acids.[A256267] There are several proposed mechanisms of choleretic actions of UDCA: UDCA increases intracellular calcium levels, stimulating transport proteins and vesicular exocytosis in cholestatic hepatocytes.[A256267] UDCA may also upregulate the expression of membrane transport proteins like the chloride-bicarbonate anion exchanger (AE2),[A256267,A256458] which is involved in biliary secretion and is often observed to be defective in primary biliary cholangitis.[A256448] In rats, UDCA reduced hepatic expression of major histocompatibility complex (MHC) class I antigens, suggesting immunomodulating effects.[A256267] UDCA acts as a partial agonist at the bile acid receptor, also known as the farnesoid X receptor (FXR), and has negligible effects on cholesterol and lipid synthesis.[A256272]", "neighbor_flag": "Y", "pubmed_ids": [19747134, 18826220, 9973208, 24929818], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "XJLXINKUBYWONI-NNYOXOHSSA-N", "cofactor_smiles": "NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O", "cofactor_chem_comp_id": "NAP", "cofactor_name": "Nicotinamide adenine dinucleotide phosphate", "cofactor_resource_id": "DB03461", "neighbor_flag": "Y", "pubmed_ids": [17139284, 17016423], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "RUDATBOHQWOJDD-BSWAIDMHSA-N", "cofactor_smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O", "cofactor_chem_comp_id": "JN3", "cofactor_name": "Chenodeoxycholic acid", "cofactor_resource_id": "DB06777", "mechanism_of_action": "Chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. These actions contribute to biliary cholesterol desaturation and gradual dissolution of radiolucent cholesterol gallstones in the presence of a gall-bladder visualized by oral cholecystography. Bile acids may also bind the the bile acid receptor (FXR) which regulates the synthesis and transport of bile acids. ", "neighbor_flag": "N", "pubmed_ids": [8486699], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "MUMGGOZAMZWBJJ-KZYORJDKSA-N", "cofactor_smiles": "[H][C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C", "cofactor_chem_comp_id": "FFA", "cofactor_name": "Epitestosterone", "cofactor_resource_id": "DB07768", "neighbor_flag": "Y", "pubmed_ids": [10592235], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "XRVDGNKRPOAQTN-FQEVSTJZSA-N", "cofactor_smiles": "CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N", "cofactor_chem_comp_id": "JEU", "cofactor_name": "Ozanimod", "cofactor_resource_id": "DB12612", "mechanism_of_action": "Sphingosine\u20101\u2010phosphate (S1P) is an important phospholipid that binds to various G\u2010protein\u2010coupled receptor subtypes, which can be identified as S1P1\u20135R. S1P and the receptors it binds to perform regular functions in the immune, cardiovascular, pulmonary, and nervous system.[A189321,A192744] S1P can be expressed ubiquitously, playing an important role in regulating inflammation.  S1P1R, S1P2R, and S1P3R receptors can be found in the cardiovascular, immune, and central nervous systems. S1P4R is found on lymphocytic and hematopoietic cells, while S1P5R expression is found only on the spleen (on natural killer cells) or in the central nervous system.[A189333]\r\n\r\nOzanimod is a selective modulator of S1P receptors and binds to S1P1R and S1P5R subtypes.[A189333] The mechanism of action of ozanimod is not fully understood, but this drug likely reduces the migration of lymphocytes that usually aggravate the inflammation associated with MS.[L12582]", "neighbor_flag": "N", "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "LPLVUJXQOOQHMX-QWBHMCJMSA-N", "cofactor_smiles": "[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O", "cofactor_name": "Glycyrrhizic acid", "cofactor_resource_id": "DB13751", "mechanism_of_action": "Glycyrrhizic acid can be found in the alpha and beta forms. The alpha form is predominant in the liver and duodenum and thus, it is thought that the anti-inflammatory liver effect of this drug are mainly due to the action of this isomer. Glycyrrhizic acid anti-inflammatory effect is generated via suppression of TNF alpha and caspase 3. It also inhibits the translocation of NFkB into the nuclei and conjugates free radicals. Some studies have shown a glycyrrhizic-driven inhibition of CD4+ T cell proliferation via JNK, ERK and PI3K/AKT.[A33062]\r\n\r\nThe antiviral activity of glycyrrhizic acid includes the inhibition of viral replication and immune regulation.[A33062] The antiviral activity of glycyrrhizic acid seems to be of a broad spectrum and be able to cover several different viral types such as vaccinia virus, herpes simplex virus, Newcastle disease virus and vesicular stomatitis virus.[A33063]\r\n\r\nThe effect of glycyrrhizic acid on metabolism is thought to be related to its inhibitory activity towards 11-beta-hydroxysteroid dehydrogenase type 1 which in turn decreases the activity of hexose-6-phosphate dehydrogenase. On the other hand, some studies have shown a potential lipoprotein lipase induction in non-hepatic tissues and thus it is suggested to enhance dyslipidemic conditions.[A33063]", "neighbor_flag": "N", "pubmed_ids": [10652246], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P52895"}, {"cofactor_in_ch_ikey": "BOPGDPNILDQYTO-NNYOXOHSSA-N", "cofactor_smiles": "NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O", "cofactor_chem_comp_id": "NAI", "cofactor_name": "NADH", "cofactor_resource_id": "DB00157", "mechanism_of_action": "NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.", "neighbor_flag": "N", "pubmed_ids": [2615366, 3463506, 11060293], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "BLXXJMDCKKHMKV-UHFFFAOYSA-N", "cofactor_smiles": "COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2", "cofactor_chem_comp_id": "NBO", "cofactor_name": "Nabumetone", "cofactor_resource_id": "DB00461", "mechanism_of_action": "Nabumetone's active metabolite, 6-MNA, is an inhibitor of both COX-1 and COX-2 although it exhibits some COX-2 selectivity.[label,A178903] Inhibition of COX-1 and COX-2 reduces conversion of arachidonic acid to PGs and thromboxane (TXA<sub>2</sub>). This reduction in prostanoid production is the common mechanism that mediates the effects of nambutone.\r\n\r\nPGE<sub>2</sub> is the primary PG involved in modulation of nociception.[A179023] It mediates peripheral sensitization through a variety of effects.[T116,A179023] PGE<sub>2</sub> activates the G<sub>q</sub>-coupled EP<sub>1</sub> receptor leading to increased activity of the inositol trisphosphate/phospholipase C pathway. Activation of this pathway releases intracellular stores of calcium which directly reduces action potential threshold and activates protein kinase C (PKC) which contributes to several indirect mechanisms. PGE<sub>2</sub> also activates the EP<sub>4</sub> receptor, coupled to G<sub>s</sub>, which activates the adenylyl cyclase/protein kinase A (AC/PKA) signaling pathway. PKA and PKC both contribute to the potentiation of transient receptor potential cation channel subfamily V member 1 (TRPV1) potentiation, which increases sensitivity to heat stimuli. They also activate tetrodotoxin-resistant sodium channels and inhibit inward potassium currents. PKA further contributes to the activation of the P2X3 purine receptor and sensitization of T-type calcium channels. The activation and sensitization of depolarizing ion channels and inhibition of inward potassium currents serve to reduce the intensity of stimulus necessary to generate action potentials in nociceptive sensory afferents. PGE<sub>2</sub> act via EP<sub>3</sub> to increase sensitivity to bradykinin and via EP<sub>2</sub> to further increase heat sensitivity. Central sensitization occurs in the dorsal horn of the spinal cord and is mediated by the EP<sub>2</sub> receptor which couples to G<sub>s</sub>. Pre-synaptically, this receptor increases the release of pro-nociceptive neurotransmitters glutamate, CGRP, and substance P. Post-synaptically it increases the activity of AMPA and NMDA receptors and produces inhibition of inhibitory glycinergic neurons. Together these lead to a reduced threshold of activating, allowing low intensity stimuli to generate pain signals. PGI<sub>2</sub> is known to play a role via its G<sub>s</sub>-coupled IP receptor although the magnitude of its contribution varies. It has been proposed to be of greater importance in painful inflammatory conditions such as arthritis. By limiting sensitization, both peripheral and central, via these pathways NSAIDs can effectively reduce inflammatory pain.\r\n\r\nPGI<sub>2</sub> and PGE<sub>2</sub> contribute to acute inflammation via their IP and EP<sub>2</sub> receptors.[T116,A179044] Similarly to \u03b2 adrenergic receptors these are G<sub>s</sub>-coupled and mediate vasodilation through the AC/PKA pathway. PGE<sub>2</sub> also contributes by increasing leukocyte adhesion to the endothelium and attracts the cells to the site of injury.[T116] PGD<sub>2</sub> plays a role in the activation of endothelial cell release of cytokines through its DP<sub>1</sub> receptor.[A179044] PGI<sub>2</sub> and PGE<sub>2</sub> modulate T-helper cell activation and differentiation through IP, EP<sub>2</sub>, and EP<sub>4</sub> receptors which is believed to be an important activity in the pathology of arthritic conditions. By limiting the production of these PGs at the site of injury, NSAIDs can reduce inflammation.\r\n\r\nPGE<sub>2</sub> can cross the blood-brain barrier and act on excitatory G<sub>q</sub> EP<sub>3</sub> receptors on thermoregulatory neurons in the hypothalamus.[T116] This activation triggers an increase in heat-generation and a reduction in heat-loss to produce a fever. NSAIDs prevent the generation of PGE<sub>2</sub> thereby reducing the activity of these neurons.\r\n\r\nThe adverse effects of NSAIDs stem from the protective and regulatory roles of prostanoids which have been well-characterized.[T116] PGI<sub>2</sub> and PGE<sub>2</sub> regulate blood flow to the kidney by similar mechanisms to the vasodilation they produce in inflammation. Prevention of this regulation by NSAIDs produces vasoconstriction which limits renal function by reducing blood flow and the hydrostatic pressure which drives filtration. PGE<sub>2</sub> also regulates gastric protection via EP<sub>3</sub> receptors which are, in this location, coupled to G<sub>i</sub> which inhibits the AC/PKA pathway. This reduces the secretion of protons by H<sup>+</sup>/K<sup>+</sup> ATPase in parietal cells and increases the secretion of mucus and HCO<sub>3</sub><sup>-</sup> by superficial endothelial cells. Disruption of this protective action by NSAIDs lead to ulceration of the gastric mucosa. Lastly, disruption of PGI<sub>2</sub>, which opposes platelet aggregation, generation by COX-2 selective agents leads to an imbalance with TXA<sub>2</sub> generated by COX-1, which promotes aggregation of platelets, leading to increased risk of thrombosis. Since nabumetone is somewhat COX-2 selective it is thought to promote this imbalance and increase thrombotic risk.[A178903]", "neighbor_flag": "N", "pubmed_ids": [24659525], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "CTRLABGOLIVAIY-UHFFFAOYSA-N", "cofactor_smiles": "NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2", "cofactor_name": "Oxcarbazepine", "cofactor_resource_id": "DB00776", "mechanism_of_action": "The exact mechanism through which oxcarbazepine and its active metaoblite, MHD, exert their anti-epileptic effects is unclear, but is thought to primarily involve the blockade of voltage-gated sodium channels.[L8627,L8630,L8633,A186104] The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity. Both oxcarbazepine and MHD are thought to inhibit seizure activity by binding to the inactive state of voltage-gated sodium channels, thus prolonging the period in which the receptor is unavailable for action potential propagation.[A186101] This helps to stabilize hyperexcited neuronal membranes, inhibit repetitive neuron firing, and prevent the spread of seizure activity within the CNS without affecting normal neuronal transmission.[L8627,L8630,L8633]\r\n\r\nIncreased potassium conductance and modulation of voltage-activated calcium channels is also thought to play a role in the anti-seizure activity of oxcarbazepine.[L8627,L8630,L8633] Inhibition of glutamatergic activity was thought to contribute to oxcarbazepine's activity[A34516], but this effect could not be replicated _in vivo_.[A186104]", "neighbor_flag": "N", "pubmed_ids": [25063510], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "YGSDEFSMJLZEOE-UHFFFAOYSA-N", "cofactor_smiles": "OC(=O)C1=CC=CC=C1O", "cofactor_chem_comp_id": "SAL", "cofactor_name": "Salicylic acid", "cofactor_resource_id": "DB00936", "mechanism_of_action": "Salicylic acid directly and reversibly inhibits COX-1 and COX-2 to decrease conversion of arachidonic acid to precursors of prostaglandins and thromboxanes.[A33150, A274656] Salicylate's use in rheumatic diseases is due to it's analgesic and anti-inflammatory activity. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. Salicylic acid allows cells of the epidermis to more readily slough off. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid competitively inhibits oxidation of uridine-5-diphosphoglucose (UDPG) with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of the glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to a phenolic acceptor. Inhibition of mucopoly saccharide synthesis is likely responsible for the slowing of wound healing with salicylates.", "neighbor_flag": "N", "pubmed_ids": [18045204], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "BSYNRYMUTXBXSQ-UHFFFAOYSA-N", "cofactor_smiles": "CC(=O)OC1=CC=CC=C1C(O)=O", "cofactor_chem_comp_id": "AIN", "cofactor_name": "Acetylsalicylic acid", "cofactor_resource_id": "DB00945", "mechanism_of_action": "Acetylsalicylic acid (ASA) blocks prostaglandin synthesis. It is non-selective for COX-1 and COX-2 enzymes [A177241, A10989, A32682]. Inhibition of COX-1 results in the inhibition of platelet aggregation for about 7-10 days (average platelet lifespan). The acetyl group of acetylsalicylic acid binds with a serine residue of the cyclooxygenase-1 (COX-1) enzyme, leading to irreversible inhibition. This prevents the production of pain-causing prostaglandins. This process also stops the conversion of arachidonic acid to thromboxane A2 (TXA2), which is a potent inducer of platelet aggregation [FDA label].  Platelet aggregation can result in clots and harmful venous and arterial thromboembolism, leading to conditions such as pulmonary embolism and stroke. \r\n\r\nIt is important to note that there is 60% homology between the protein structures of COX-1 and COX-2. ASA binds to serine 516 residue on the active site of COX-2 in the same fashion as its binding to the serine 530 residue located on the active site of COX-1. The active site of COX-2 is, however, slightly larger than the active site of COX-1, so that arachidonic acid (which later becomes prostaglandins) manages to bypass the aspirin molecule inactivating COX-2 [A32682, A177256].  ASA, therefore, exerts more action on the COX-1 receptor rather than on the COX-2 receptor [A177268]. A higher dose of acetylsalicylic acid is required for COX-2 inhibition [A177325]. ", "neighbor_flag": "N", "pubmed_ids": [18045204], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "VHRSUDSXCMQTMA-PJHHCJLFSA-N", "cofactor_smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C", "cofactor_name": "Methylprednisolone", "cofactor_resource_id": "DB00959", "mechanism_of_action": "The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]\r\n\r\nGlucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]\r\n\r\nLower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]", "neighbor_flag": "N", "pubmed_ids": [24171394, 3732369], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "YMTINGFKWWXKFG-UHFFFAOYSA-N", "cofactor_smiles": "CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1", "cofactor_chem_comp_id": "J3O", "cofactor_name": "Fenofibrate", "cofactor_resource_id": "DB01039", "mechanism_of_action": "Fenofibrate activates peroxisome proliferator activated receptor alpha (PPAR\u03b1), increasing lipolysis, activating lipoprotein lipase, and reducing apoprotein C-III.[A186002,L8588,L8591] PPAR\u03b1 is a nuclear receptor and its activation alters lipid, glucose, and amino acid homeostasis.[A186002] Activation of PPAR\u03b1 activates transcription of gene transcription and translation that generates peroxisomes filled with hydrogen peroxide, reactive oxygen species, and hydroxyl radicals that also participate in lipolysis.[A186005] This mechanism of increased lipid metabolism is also associated with increased oxidative stress on the liver.[A186005] In rare cases this stress can lead to cirrhosis and chronic active hepatitis.[A186002,L8588,L8591]", "neighbor_flag": "N", "pubmed_ids": [27599626], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "XJLXINKUBYWONI-NNYOXOHSSA-N", "cofactor_smiles": "NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O", "cofactor_chem_comp_id": "NAP", "cofactor_name": "Nicotinamide adenine dinucleotide phosphate", "cofactor_resource_id": "DB03461", "neighbor_flag": "Y", "pubmed_ids": [10592235], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "FTVWIRXFELQLPI-ZDUSSCGKSA-N", "cofactor_smiles": "[H][C@]1(CC(=O)C2=C(O1)C=C(O)C=C2O)C1=CC=C(O)C=C1", "cofactor_chem_comp_id": "NAR", "cofactor_name": "Naringenin", "cofactor_resource_id": "DB03467", "neighbor_flag": "N", "pubmed_ids": [16962702], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "DHZVWQPHNWDCFS-UHFFFAOYSA-N", "cofactor_smiles": "OC(=O)C1=C(O)C(I)=CC(I)=C1", "cofactor_chem_comp_id": "DIU", "cofactor_name": "2-HYDROXY-3,5-DIIODOBENZOIC ACID", "cofactor_resource_id": "DB04674", "neighbor_flag": "N", "pubmed_ids": [18045204], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "HOIIHACBCFLJET-SFTDATJTSA-N", "cofactor_smiles": "[H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C", "cofactor_chem_comp_id": "92S", "cofactor_name": "Lumateperone", "cofactor_resource_id": "DB06077", "mechanism_of_action": "There is much to learn about the pathophysiology of schizophrenia; however, dopamine abnormalities, specifically in the prefrontal and mesolimbic brain regions, are consistent in people with schizophrenia.[A189156] In addition to dopamine, other neurotransmitters such as serotonin, glutamate, GABA and acetylcholine are thought to play a role.[A189156] \r\n\r\nLumateperone is unique among second generation antipsychotics based on its target profile and dopamine D2 receptor occupancy.[A189093,A188991] Unlike other antipsychotics, lumateperone has partial agonist activity at presynaptic dopamine (D2) receptors, resulting in reduced presynaptic release of dopamine, and antagonistic activity at postsynaptic dopamine (D2) receptors.[A188991] These characteristics allow lumateperone to efficiently reduce dopamine signaling.[A188991]\r\n\r\nLumateperone also targets dopamine (D1) receptors, and a useful secondary result of D1 activation is increased glutamatergic N-methyl-D-aspartate (NMDA) GluN2B receptor phosphorylation.[A189093,A188991,A188985] This is significant since NMDA mediated glutamate signaling appears to be impaired in patients who have schizophrenia.[A189093] \r\n\r\nFinally, lumateperone is capable of modulating serotonin by inhibiting serotonin transporters (SERT), and by behaving as a 5-HT2A receptor antagonist.[A188991] \r\n", "neighbor_flag": "N", "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "MUMGGOZAMZWBJJ-KZYORJDKSA-N", "cofactor_smiles": "[H][C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C", "cofactor_chem_comp_id": "FFA", "cofactor_name": "Epitestosterone", "cofactor_resource_id": "DB07768", "neighbor_flag": "Y", "pubmed_ids": [10592235], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "PBBGSZCBWVPOOL-HDICACEKSA-N", "cofactor_smiles": "[H][C@](CC)(C1=CC=C(O)C=C1)[C@]([H])(CC)C1=CC=C(O)C=C1", "cofactor_chem_comp_id": "HXS", "cofactor_name": "Hexestrol", "cofactor_resource_id": "DB07931", "neighbor_flag": "N", "pubmed_ids": [10592235], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"cofactor_in_ch_ikey": "XRVDGNKRPOAQTN-FQEVSTJZSA-N", "cofactor_smiles": "CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N", "cofactor_chem_comp_id": "JEU", "cofactor_name": "Ozanimod", "cofactor_resource_id": "DB12612", "mechanism_of_action": "Sphingosine\u20101\u2010phosphate (S1P) is an important phospholipid that binds to various G\u2010protein\u2010coupled receptor subtypes, which can be identified as S1P1\u20135R. S1P and the receptors it binds to perform regular functions in the immune, cardiovascular, pulmonary, and nervous system.[A189321,A192744] S1P can be expressed ubiquitously, playing an important role in regulating inflammation.  S1P1R, S1P2R, and S1P3R receptors can be found in the cardiovascular, immune, and central nervous systems. S1P4R is found on lymphocytic and hematopoietic cells, while S1P5R expression is found only on the spleen (on natural killer cells) or in the central nervous system.[A189333]\r\n\r\nOzanimod is a selective modulator of S1P receptors and binds to S1P1R and S1P5R subtypes.[A189333] The mechanism of action of ozanimod is not fully understood, but this drug likely reduces the migration of lymphocytes that usually aggravate the inflammation associated with MS.[L12582]", "neighbor_flag": "N", "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "Q04828"}, {"binding_assay_value": 8.82, "binding_assay_value_type": "pKi", "cofactor_smiles": "O=C(O)c1cc(-c2ccccc2)cc(F)c1O", "cofactor_resource_id": "CHEMBL1275725", "neighbor_flag": "N", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.85, "binding_assay_value_type": "pKi", "cofactor_smiles": "CCCCc1ccc(-c2cc(Cl)c(O)c(C(=O)O)c2)cc1", "cofactor_resource_id": "CHEMBL1277647", "neighbor_flag": "N", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.77, "binding_assay_value_type": "pKi", "cofactor_smiles": "Cc1cccc(-c2cc(Cl)c(O)c(C(=O)O)c2)c1", "cofactor_resource_id": "CHEMBL1275704", "neighbor_flag": "N", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.68, "binding_assay_value_type": "pKi", "cofactor_smiles": "O=C(O)c1cc(-c2ccccc2)cc(Cl)c1O", "cofactor_chem_comp_id": "5P3", "cofactor_resource_id": "CHEMBL1275703", "neighbor_flag": "Y", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.58, "binding_assay_value_type": "pKi", "cofactor_smiles": "O=C(O)c1cc(-c2ccc(OC(F)(F)F)cc2)cc(Cl)c1O", "cofactor_resource_id": "CHEMBL1277741", "neighbor_flag": "N", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.54, "binding_assay_value_type": "pKi", "cofactor_smiles": "CC(C)Cc1ccc(-c2cc(Cl)c(O)c(C(=O)O)c2)cc1", "cofactor_resource_id": "CHEMBL1277648", "neighbor_flag": "N", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.2, "binding_assay_value_type": "pKi", "cofactor_smiles": "Cc1ccc(-c2cc(Cl)c(O)c(C(=O)O)c2)cc1", "cofactor_resource_id": "CHEMBL1275723", "neighbor_flag": "N", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.16, "binding_assay_value_type": "pKi", "cofactor_smiles": "O=C(O)c1cc(Cl)cc(Cl)c1O", "cofactor_chem_comp_id": "C2U", "cofactor_resource_id": "CHEMBL449129", "neighbor_flag": "Y", "pubmed_ids": [18620380], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.09, "binding_assay_value_type": "pKi", "cofactor_smiles": "O=C(O)c1cc(Br)cc(Br)c1O", "cofactor_resource_id": "CHEMBL447448", "neighbor_flag": "N", "pubmed_ids": [19397269], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 7.06, "binding_assay_value_type": "pKi", "cofactor_smiles": "O=C(O)c1cc(-c2ccccc2)cc(Br)c1O", "cofactor_resource_id": "CHEMBL387536", "neighbor_flag": "N", "pubmed_ids": [19397269], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15823"}, {"binding_assay_value": 8.22, "binding_assay_value_type": "pIC50", "cofactor_smiles": "O=C(O)c1cc(Cl)cc(Cl)c1O", "cofactor_chem_comp_id": "C2U", "cofactor_resource_id": "CHEMBL449129", "neighbor_flag": "Y", "pubmed_ids": [19397269], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15942"}, {"binding_assay_value": 7.48, "binding_assay_value_type": "pIC50", "cofactor_smiles": "O=C1OC(c2cc(Br)c(O)c(Br)c2)(c2cc(Br)c(O)c(Br)c2)c2ccccc21", "cofactor_resource_id": "CHEMBL521800", "neighbor_flag": "N", "pubmed_ids": [19397269], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15942"}, {"binding_assay_value": 7.0, "binding_assay_value_type": "pIC50", "cofactor_smiles": "O=C(O)c1cc(-c2ccccc2)cc(Cl)c1O", "cofactor_chem_comp_id": "5P3", "cofactor_resource_id": "CHEMBL1275703", "neighbor_flag": "Y", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15942"}, {"binding_assay_value": 6.85, "binding_assay_value_type": "pKi", "cofactor_smiles": "O=C(O)c1cc(Br)cc(-c2ccccc2)c1O", "cofactor_resource_id": "CHEMBL331146", "neighbor_flag": "N", "pubmed_ids": [19397269], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15942"}, {"binding_assay_value": 6.52, "binding_assay_value_type": "pIC50", "cofactor_smiles": "O=C(O)c1cc(-c2ccccc2)cc(F)c1O", "cofactor_resource_id": "CHEMBL1275725", "neighbor_flag": "N", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15942"}, {"binding_assay_value": 6.47, "binding_assay_value_type": "pKi", "cofactor_smiles": "COC(C)c1ccc(-c2cc(Cl)c(O)c(C(=O)O)c2)cc1", "cofactor_resource_id": "CHEMBL1277646", "neighbor_flag": "N", "pubmed_ids": [20850205], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15942"}, {"binding_assay_value": 6.34, "binding_assay_value_type": "pIC50", "cofactor_smiles": "O=C(O)c1cc(-c2ccccc2)cc(Br)c1O", "cofactor_resource_id": "CHEMBL387536", "neighbor_flag": "N", "pubmed_ids": [19397269], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15942"}, {"binding_assay_value": 6.14, "binding_assay_value_type": "pIC50", "cofactor_smiles": "O=C(O)C1CCCN(S(=O)(=O)c2ccc(-c3cccc(-c4ccccc4)c3)cc2)C1", "cofactor_resource_id": "CHEMBL2172064", "neighbor_flag": "N", "pubmed_ids": [22877157], "resource_name": "Pharos", "resource_version": "6.13.4", "target_resource_id": "15942"}], "rcsb_id": "1MRQ_1"}